Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]

Silke Gillessen; Gerhardt Attard; Tomasz M. Beer; Himisha Beltran; Anders Bjartell; Alberto Bossi; Alberto Briganti; Rob G. Bristow; Kim N. Chi; Noel Clarke; Ian D. Davis; Johann de Bono; Charles G. Drake; Ignacio Duran; Ros Eeles; Eleni Efstathiou; Christopher P. Evans; Stefano Fanti; Felix Y. Feng; Karim Fizazi; Mark Frydenberg; Martin Gleave; Susan Halabi; Axel Heidenreich; Daniel Heinrich; Celestia (Tia) S. Higano; Michael S. Hofman; Maha Hussain; Nicolas James; Ravindran Kanesvaran; Philip Kantoff; Raja B. Khauli; Raya Leibowitz; Chris Logothetis; Fernando Maluf; Robin Millman; Alicia K. Morgans; Michael J. Morris; Nicolas Mottet; Hind Mrabti; Declan G. Murphy; Vedang Murthy; William K. Oh; Piet Ost; Joe M. O'Sullivan; Anwar R. Padhani; Chris Parker; Darren M.C. Poon; Colin C. Pritchard; Robert E. Reiter; Mack Roach; Mark Rubin; Charles J. Ryan; Fred Saad; Juan Pablo Sade; Oliver Sartor; Howard I. Scher; Neal Shore; Eric Small; Matthew Smith; Howard Soule; Cora N. Sternberg; Thomas Steuber; Hiroyoshi Suzuki; Christopher Sweeney; Matthew R. Sydes; Mary Ellen Taplin; Bertrand Tombal; Levent Türkeri; Inge van Oort; Almudena Zapatero; Aurelius Omlin

doi:10.1016/j.eururo.2020.01.012

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]

Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, Alberto Briganti, Rob G. Bristow, Kim N. Chi, Noel Clarke, Ian D. Davis, Johann de Bono, Charles G. Drake, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Karim FizaziMark Frydenberg, Martin Gleave, Susan Halabi, Axel Heidenreich, Daniel Heinrich, Celestia (Tia) S. Higano, Michael S. Hofman, Maha Hussain, Nicolas James, Ravindran Kanesvaran, Philip Kantoff, Raja B. Khauli, Raya Leibowitz, Chris Logothetis, Fernando Maluf, Robin Millman, Alicia K. Morgans, Michael J. Morris, Nicolas Mottet, Hind Mrabti, Declan G. Murphy, Vedang Murthy, William K. Oh, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Chris Parker, Darren M.C. Poon, Colin C. Pritchard, Robert E. Reiter, Mack Roach, Mark Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Neal Shore, Eric Small, Matthew Smith, Howard Soule, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki, Christopher Sweeney, Matthew R. Sydes, Mary Ellen Taplin, Bertrand Tombal, Levent Türkeri, Inge van Oort, Almudena Zapatero, Aurelius Omlin

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

43 Scopus citations

Abstract

At the Advanced Prostate Cancer Consensus Conference (APCCC) 2019, 10 important areas of controversy in advanced prostate cancer management were identified and discussed, and experts voted on 123 predefined consensus questions. The full report of the results is summarised here.

Original language	English (US)
Pages (from-to)	508-547
Number of pages	40
Journal	European Urology
Volume	77
Issue number	4
DOIs	https://doi.org/10.1016/j.eururo.2020.01.012
State	Published - Apr 2020

Bibliographical note

Funding Information:
Although there was a range of opinions regarding the starting dose of chemotherapy in patients of East Asian ethnicity, 60% of panellists recommended starting chemotherapy at a reduced dose. This strategy is supported by the experience of physicians from the Asia-Pacific region and by limited studies. Although no large prospective clinical trials have compared dosing strategies (eg, a reduced dose vs a full dose with G-CSF support) in this population, the available literature suggests that antitumour activity is comparable, even if a reduced dose is used [174,175] .

Funding Information:
Funding/Support and role of the sponsor: We gratefully acknowledge the following organisations for providing financial support for the APCCC 2019: Canton of Basel, European School of Oncology (ESO), Swiss Cancer League, Swiss Oncology Research Network (SAKK), Prostate Cancer Foundation (PCF), and Cantonal Hospital St. Gallen. We would like to especially thank the Movember Foundation for generously supporting the APCCC 2019. Special thanks also to the EAU, the European Organisation for Research and Treatment of Cancer (EORTC), the European Society for Radiotherapy and Oncology (ESTRO), and the European School of Oncology (ESO) for their endorsements. We also acknowledge sponsorship from several for-profit organisations, including Astellas, Bayer Health Care, AstraZeneca, MSD, Pfizer Oncology, Janssen Oncology, Sanofi Genzyme, Amgen, Clovis Oncology, Ferring Pharmaceuticals, Ipsen, Roche, Tolmar, Advanced Accelerator Applications, and Orion Pharma (details on sponsorship are available at www.apccc.org ). These for-profit organisations supported the conference financially but had no input on the scientific content or the final publication. Ian D. Davis is supported by a National Health and Medical Research Council (NHMRC) Practitioner Fellowship (APP1102604). Michael S. Hofman is supported by a clinical fellowship award from the Peter MacCallum Foundation.

Keywords

Advanced prostate cancer
Castration-naïve prostate cancer
Castration-resistant prostate cancer
Genetics
High-risk localised prostate cancer
Hormone-sensitive prostate cancer
Imaging
Oligometastatic prostate cancer
Overall survival
Progression-free survival
Prostate cancer treatment
Tumour genomic profiling

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Access

10.1016/j.eururo.2020.01.012

Fingerprint Dive into the research topics of 'Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]'. Together they form a unique fingerprint.

Cite this

Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., Bossi, A., Briganti, A., Bristow, R. G., Chi, K. N., Clarke, N., Davis, I. D., de Bono, J., Drake, C. G., Duran, I., Eeles, R., Efstathiou, E., Evans, C. P., Fanti, S., Feng, F. Y., ... Omlin, A. (2020). Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]. European Urology, 77(4), 508-547. https://doi.org/10.1016/j.eururo.2020.01.012

Management of Patients with Advanced Prostate Cancer : Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]. / Gillessen, Silke; Attard, Gerhardt; Beer, Tomasz M.; Beltran, Himisha; Bjartell, Anders; Bossi, Alberto; Briganti, Alberto; Bristow, Rob G.; Chi, Kim N.; Clarke, Noel; Davis, Ian D.; de Bono, Johann; Drake, Charles G.; Duran, Ignacio; Eeles, Ros; Efstathiou, Eleni; Evans, Christopher P.; Fanti, Stefano; Feng, Felix Y.; Fizazi, Karim; Frydenberg, Mark; Gleave, Martin; Halabi, Susan; Heidenreich, Axel; Heinrich, Daniel; Higano, Celestia (Tia) S.; Hofman, Michael S.; Hussain, Maha; James, Nicolas; Kanesvaran, Ravindran; Kantoff, Philip; Khauli, Raja B.; Leibowitz, Raya; Logothetis, Chris; Maluf, Fernando; Millman, Robin; Morgans, Alicia K.; Morris, Michael J.; Mottet, Nicolas; Mrabti, Hind; Murphy, Declan G.; Murthy, Vedang; Oh, William K.; Ost, Piet; O'Sullivan, Joe M.; Padhani, Anwar R.; Parker, Chris; Poon, Darren M.C.; Pritchard, Colin C.; Reiter, Robert E.; Roach, Mack; Rubin, Mark; Ryan, Charles J.; Saad, Fred; Sade, Juan Pablo; Sartor, Oliver; Scher, Howard I.; Shore, Neal; Small, Eric; Smith, Matthew; Soule, Howard; Sternberg, Cora N.; Steuber, Thomas; Suzuki, Hiroyoshi; Sweeney, Christopher; Sydes, Matthew R.; Taplin, Mary Ellen; Tombal, Bertrand; Türkeri, Levent; van Oort, Inge; Zapatero, Almudena; Omlin, Aurelius.

In: European Urology, Vol. 77, No. 4, 04.2020, p. 508-547.

Research output: Contribution to journal › Article › peer-review

Gillessen, S, Attard, G, Beer, TM, Beltran, H, Bjartell, A, Bossi, A, Briganti, A, Bristow, RG, Chi, KN, Clarke, N, Davis, ID, de Bono, J, Drake, CG, Duran, I, Eeles, R, Efstathiou, E, Evans, CP, Fanti, S, Feng, FY, Fizazi, K, Frydenberg, M, Gleave, M, Halabi, S, Heidenreich, A, Heinrich, D, Higano, CTS, Hofman, MS, Hussain, M, James, N, Kanesvaran, R, Kantoff, P, Khauli, RB, Leibowitz, R, Logothetis, C, Maluf, F, Millman, R, Morgans, AK, Morris, MJ, Mottet, N, Mrabti, H, Murphy, DG, Murthy, V, Oh, WK, Ost, P, O'Sullivan, JM, Padhani, AR, Parker, C, Poon, DMC, Pritchard, CC, Reiter, RE, Roach, M, Rubin, M, Ryan, CJ, Saad, F, Sade, JP, Sartor, O, Scher, HI, Shore, N, Small, E, Smith, M, Soule, H, Sternberg, CN, Steuber, T, Suzuki, H, Sweeney, C, Sydes, MR, Taplin, ME, Tombal, B, Türkeri, L, van Oort, I, Zapatero, A & Omlin, A 2020, 'Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]', European Urology, vol. 77, no. 4, pp. 508-547. https://doi.org/10.1016/j.eururo.2020.01.012

Gillessen, Silke ; Attard, Gerhardt ; Beer, Tomasz M. ; Beltran, Himisha ; Bjartell, Anders ; Bossi, Alberto ; Briganti, Alberto ; Bristow, Rob G. ; Chi, Kim N. ; Clarke, Noel ; Davis, Ian D. ; de Bono, Johann ; Drake, Charles G. ; Duran, Ignacio ; Eeles, Ros ; Efstathiou, Eleni ; Evans, Christopher P. ; Fanti, Stefano ; Feng, Felix Y. ; Fizazi, Karim ; Frydenberg, Mark ; Gleave, Martin ; Halabi, Susan ; Heidenreich, Axel ; Heinrich, Daniel ; Higano, Celestia (Tia) S. ; Hofman, Michael S. ; Hussain, Maha ; James, Nicolas ; Kanesvaran, Ravindran ; Kantoff, Philip ; Khauli, Raja B. ; Leibowitz, Raya ; Logothetis, Chris ; Maluf, Fernando ; Millman, Robin ; Morgans, Alicia K. ; Morris, Michael J. ; Mottet, Nicolas ; Mrabti, Hind ; Murphy, Declan G. ; Murthy, Vedang ; Oh, William K. ; Ost, Piet ; O'Sullivan, Joe M. ; Padhani, Anwar R. ; Parker, Chris ; Poon, Darren M.C. ; Pritchard, Colin C. ; Reiter, Robert E. ; Roach, Mack ; Rubin, Mark ; Ryan, Charles J. ; Saad, Fred ; Sade, Juan Pablo ; Sartor, Oliver ; Scher, Howard I. ; Shore, Neal ; Small, Eric ; Smith, Matthew ; Soule, Howard ; Sternberg, Cora N. ; Steuber, Thomas ; Suzuki, Hiroyoshi ; Sweeney, Christopher ; Sydes, Matthew R. ; Taplin, Mary Ellen ; Tombal, Bertrand ; Türkeri, Levent ; van Oort, Inge ; Zapatero, Almudena ; Omlin, Aurelius. / Management of Patients with Advanced Prostate Cancer : Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]. In: European Urology. 2020 ; Vol. 77, No. 4. pp. 508-547.

@article{0948df1a48a8464bab2046d97efdb929,

title = "Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]",

abstract = "At the Advanced Prostate Cancer Consensus Conference (APCCC) 2019, 10 important areas of controversy in advanced prostate cancer management were identified and discussed, and experts voted on 123 predefined consensus questions. The full report of the results is summarised here.",

keywords = "Advanced prostate cancer, Castration-na{\"i}ve prostate cancer, Castration-resistant prostate cancer, Genetics, High-risk localised prostate cancer, Hormone-sensitive prostate cancer, Imaging, Oligometastatic prostate cancer, Overall survival, Progression-free survival, Prostate cancer treatment, Tumour genomic profiling",

author = "Silke Gillessen and Gerhardt Attard and Beer, {Tomasz M.} and Himisha Beltran and Anders Bjartell and Alberto Bossi and Alberto Briganti and Bristow, {Rob G.} and Chi, {Kim N.} and Noel Clarke and Davis, {Ian D.} and {de Bono}, Johann and Drake, {Charles G.} and Ignacio Duran and Ros Eeles and Eleni Efstathiou and Evans, {Christopher P.} and Stefano Fanti and Feng, {Felix Y.} and Karim Fizazi and Mark Frydenberg and Martin Gleave and Susan Halabi and Axel Heidenreich and Daniel Heinrich and Higano, {Celestia (Tia) S.} and Hofman, {Michael S.} and Maha Hussain and Nicolas James and Ravindran Kanesvaran and Philip Kantoff and Khauli, {Raja B.} and Raya Leibowitz and Chris Logothetis and Fernando Maluf and Robin Millman and Morgans, {Alicia K.} and Morris, {Michael J.} and Nicolas Mottet and Hind Mrabti and Murphy, {Declan G.} and Vedang Murthy and Oh, {William K.} and Piet Ost and O'Sullivan, {Joe M.} and Padhani, {Anwar R.} and Chris Parker and Poon, {Darren M.C.} and Pritchard, {Colin C.} and Reiter, {Robert E.} and Mack Roach and Mark Rubin and Ryan, {Charles J.} and Fred Saad and Sade, {Juan Pablo} and Oliver Sartor and Scher, {Howard I.} and Neal Shore and Eric Small and Matthew Smith and Howard Soule and Sternberg, {Cora N.} and Thomas Steuber and Hiroyoshi Suzuki and Christopher Sweeney and Sydes, {Matthew R.} and Taplin, {Mary Ellen} and Bertrand Tombal and Levent T{\"u}rkeri and {van Oort}, Inge and Almudena Zapatero and Aurelius Omlin",

note = "Funding Information: Although there was a range of opinions regarding the starting dose of chemotherapy in patients of East Asian ethnicity, 60% of panellists recommended starting chemotherapy at a reduced dose. This strategy is supported by the experience of physicians from the Asia-Pacific region and by limited studies. Although no large prospective clinical trials have compared dosing strategies (eg, a reduced dose vs a full dose with G-CSF support) in this population, the available literature suggests that antitumour activity is comparable, even if a reduced dose is used [174,175] . Funding Information: Funding/Support and role of the sponsor: We gratefully acknowledge the following organisations for providing financial support for the APCCC 2019: Canton of Basel, European School of Oncology (ESO), Swiss Cancer League, Swiss Oncology Research Network (SAKK), Prostate Cancer Foundation (PCF), and Cantonal Hospital St. Gallen. We would like to especially thank the Movember Foundation for generously supporting the APCCC 2019. Special thanks also to the EAU, the European Organisation for Research and Treatment of Cancer (EORTC), the European Society for Radiotherapy and Oncology (ESTRO), and the European School of Oncology (ESO) for their endorsements. We also acknowledge sponsorship from several for-profit organisations, including Astellas, Bayer Health Care, AstraZeneca, MSD, Pfizer Oncology, Janssen Oncology, Sanofi Genzyme, Amgen, Clovis Oncology, Ferring Pharmaceuticals, Ipsen, Roche, Tolmar, Advanced Accelerator Applications, and Orion Pharma (details on sponsorship are available at www.apccc.org ). These for-profit organisations supported the conference financially but had no input on the scientific content or the final publication. Ian D. Davis is supported by a National Health and Medical Research Council (NHMRC) Practitioner Fellowship (APP1102604). Michael S. Hofman is supported by a clinical fellowship award from the Peter MacCallum Foundation. ",

year = "2020",

month = apr,

doi = "10.1016/j.eururo.2020.01.012",

language = "English (US)",

volume = "77",

pages = "508--547",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - Management of Patients with Advanced Prostate Cancer

T2 - Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]

AU - Gillessen, Silke

AU - Attard, Gerhardt

AU - Beer, Tomasz M.

AU - Beltran, Himisha

AU - Bjartell, Anders

AU - Bossi, Alberto

AU - Briganti, Alberto

AU - Bristow, Rob G.

AU - Chi, Kim N.

AU - Clarke, Noel

AU - Davis, Ian D.

AU - de Bono, Johann

AU - Drake, Charles G.

AU - Duran, Ignacio

AU - Eeles, Ros

AU - Efstathiou, Eleni

AU - Evans, Christopher P.

AU - Fanti, Stefano

AU - Feng, Felix Y.

AU - Fizazi, Karim

AU - Frydenberg, Mark

AU - Gleave, Martin

AU - Halabi, Susan

AU - Heidenreich, Axel

AU - Heinrich, Daniel

AU - Higano, Celestia (Tia) S.

AU - Hofman, Michael S.

AU - Hussain, Maha

AU - James, Nicolas

AU - Kanesvaran, Ravindran

AU - Kantoff, Philip

AU - Khauli, Raja B.

AU - Leibowitz, Raya

AU - Logothetis, Chris

AU - Maluf, Fernando

AU - Millman, Robin

AU - Morgans, Alicia K.

AU - Morris, Michael J.

AU - Mottet, Nicolas

AU - Mrabti, Hind

AU - Murphy, Declan G.

AU - Murthy, Vedang

AU - Oh, William K.

AU - Ost, Piet

AU - O'Sullivan, Joe M.

AU - Padhani, Anwar R.

AU - Parker, Chris

AU - Poon, Darren M.C.

AU - Pritchard, Colin C.

AU - Reiter, Robert E.

AU - Roach, Mack

AU - Rubin, Mark

AU - Ryan, Charles J.

AU - Saad, Fred

AU - Sade, Juan Pablo

AU - Sartor, Oliver

AU - Scher, Howard I.

AU - Shore, Neal

AU - Small, Eric

AU - Smith, Matthew

AU - Soule, Howard

AU - Sternberg, Cora N.

AU - Steuber, Thomas

AU - Suzuki, Hiroyoshi

AU - Sweeney, Christopher

AU - Sydes, Matthew R.

AU - Taplin, Mary Ellen

AU - Tombal, Bertrand

AU - Türkeri, Levent

AU - van Oort, Inge

AU - Zapatero, Almudena

AU - Omlin, Aurelius

N1 - Funding Information: Although there was a range of opinions regarding the starting dose of chemotherapy in patients of East Asian ethnicity, 60% of panellists recommended starting chemotherapy at a reduced dose. This strategy is supported by the experience of physicians from the Asia-Pacific region and by limited studies. Although no large prospective clinical trials have compared dosing strategies (eg, a reduced dose vs a full dose with G-CSF support) in this population, the available literature suggests that antitumour activity is comparable, even if a reduced dose is used [174,175] . Funding Information: Funding/Support and role of the sponsor: We gratefully acknowledge the following organisations for providing financial support for the APCCC 2019: Canton of Basel, European School of Oncology (ESO), Swiss Cancer League, Swiss Oncology Research Network (SAKK), Prostate Cancer Foundation (PCF), and Cantonal Hospital St. Gallen. We would like to especially thank the Movember Foundation for generously supporting the APCCC 2019. Special thanks also to the EAU, the European Organisation for Research and Treatment of Cancer (EORTC), the European Society for Radiotherapy and Oncology (ESTRO), and the European School of Oncology (ESO) for their endorsements. We also acknowledge sponsorship from several for-profit organisations, including Astellas, Bayer Health Care, AstraZeneca, MSD, Pfizer Oncology, Janssen Oncology, Sanofi Genzyme, Amgen, Clovis Oncology, Ferring Pharmaceuticals, Ipsen, Roche, Tolmar, Advanced Accelerator Applications, and Orion Pharma (details on sponsorship are available at www.apccc.org ). These for-profit organisations supported the conference financially but had no input on the scientific content or the final publication. Ian D. Davis is supported by a National Health and Medical Research Council (NHMRC) Practitioner Fellowship (APP1102604). Michael S. Hofman is supported by a clinical fellowship award from the Peter MacCallum Foundation.

PY - 2020/4

Y1 - 2020/4

N2 - At the Advanced Prostate Cancer Consensus Conference (APCCC) 2019, 10 important areas of controversy in advanced prostate cancer management were identified and discussed, and experts voted on 123 predefined consensus questions. The full report of the results is summarised here.

AB - At the Advanced Prostate Cancer Consensus Conference (APCCC) 2019, 10 important areas of controversy in advanced prostate cancer management were identified and discussed, and experts voted on 123 predefined consensus questions. The full report of the results is summarised here.

KW - Advanced prostate cancer

KW - Castration-naïve prostate cancer

KW - Castration-resistant prostate cancer

KW - Genetics

KW - High-risk localised prostate cancer

KW - Hormone-sensitive prostate cancer

KW - Imaging

KW - Oligometastatic prostate cancer

KW - Overall survival

KW - Progression-free survival

KW - Prostate cancer treatment

KW - Tumour genomic profiling

UR - http://www.scopus.com/inward/record.url?scp=85078459115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85078459115&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2020.01.012

DO - 10.1016/j.eururo.2020.01.012

M3 - Article

C2 - 32001144

AN - SCOPUS:85078459115

VL - 77

SP - 508

EP - 547

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 4

ER -